Docstoc

Detailed Introduction of the Projects

Document Sample
Detailed Introduction of the Projects Powered By Docstoc
					                        Detailed Introduction of the Projects

2.1      R&D, production and market promotion of Dikang injection
(Taikejining injection)
                                                                           Unit: USD 10,000

 Project    R&D, production and market promotion of              Industr
                                                                              Medicine Industry
 Name       Dikang injection (Taikejining injection)                y
Construct
  ion       R&D, market development and strategic cooperation
Contents
                                                                        Legal
            Company            Sichuan Dikang Sci&Tech
                                                                     Representativ      Sun Jilin
             Name           Pharmaceutical Industry. Co., Ltd.
                                                                          e
             Total                      Total                       Asset-liability
             Assets                   Liabilities                       ratio
                         Taikejining injection under research for Class-I new traditional Chinese
                         medicine of national standard
                         “Absorbable inner screws for bone bolting” under high-tech projects of
                         National “863” Program
                         Class-II new medicine of national standard, including Tuoerding,
            Leading
 Current                 piglitazone hydrochloride, sodium rabeprazole, anti-cold granules for
            Products
Situation                infants, Yintai lotion, Ditong Rhinities Water, compound
    of                   sulfamethoxazole, compound aminophenazone and Povifone Iodine
Company                  Suppositories etc.
                         Shenmai, shenqin, danqi, SDE, plentiful clinic Pazufloxacin products,
                         Yijin granule, Caseal capsule, Tongfengliling (anti-gout drug).
            Productio
                n        It is planned that the plant will be put into production in 2011, with an
            Capacity     anticipated sales volume up to USD 200-300 million in 2017.
             & Scale
            Operating                                                         Year
                         Year 2011      3700        Year 2012      7400                    11100
             Income                                                           2013
                                                                              Year
              Profit     Year 2011                  Year 2012
                                                                              2013
            As a kind of Class-I new medicine of national standard, Dikang injection is mainly
            used against the respiratory virus, treating upper respiratory tract infection, typical
Market      pneumonia and severe acute respiratory syndrome (SARS) which are caused by virus.
Forecast    Along with the continuous increase in the incidence rate of virus-caused infection over
   &        the past few years, especially with the emergence of HIV and its pathogenic virus as
Analysis    well as treatment of hepatitis virus infection in 1980s, R & D of anti-virus medicine is
            becoming a more and more urgent task. As per the statistics made by an
            internationally authoritative entity, the sales of anti-virus medicine exceeds USD six
 Project    R&D, production and market promotion of              Industr
                                                                              Medicine Industry
 Name       Dikang injection (Taikejining injection)                y
            billion in 2000, with an average annual rise of 20% between 1996-2000. This trend of
            steep rise will be maintained in the sales market in 2005, and the market value is
            expected to be increased to USD 16 billion in 2010.
            As per the statistics of medicine consumption database for nationwide hospitals, RMB
            187 million Yuan is spent to purchase general anti-virus medicine in the sample
            hospitals in 2004, a rise of 13.89% in 2004 and a rise of 16.51% compared with 2003.
            It can be estimated thereby that the total market share of the general anti-virus
            medicine for hospitals across the country will be more than RMB one billion Yuan. It
            can be concluded from above that the product enjoys a quite bright prospect both
            domestic and abroad.
Construct
  ion       The pre-clinic research has been completed and the production base is to be
Condition   constructed.
   s
                                                                     Foreign          USD 95.63
  Total
                                                                   Investment          million
Investme            USD 98.77 million (up to 2012)
                                                                 Self-Raised by        USD 3.14
   nt
                                                                  Enterprises           million
            After being put into production, the product will bring about an additional production
            value of RMB300-400 million Yuan each year only if it accounts for 2% of the
Economic    anti-virus medicine consumption amount of the country. Investment will be returned
 Benefits   in about four years, and it is expected that the sales volume will reach USD 200-300
            million in 2017.Thanks to its special curative effect to SARS, the product will return
            the company with greater social and economic benefits.
            Pre-clinic research on the product has been completed up to May 2005, while clinic
            research application has been submitted to the State Food & Drug Administration for
            approval, and the issue is being handled. To form independent intellectual property
            right, a great number of preliminary tasks have been performed such as application for
            national and international patent.
            The following pre-clinic researches have been completed:
                        1. Research on raw materials and preparation technology (including
            research on extract of raw materials, preparation of derivative as well as preparation of
Prelimina   injection etc.)
ry Tasks                2. Research on quality standard
                        3. Hemolysis test
                        4. Irritability test
                        5. Stability test
                        6. General pharmacological research
                        7. In-vitro antiviral test in pharmacodynamics
                        8. Acute toxicity test
                      9. In-vivo antiviral test in pharmacodynamics
                      10. Long-term toxicity test
 Project    R&D, production and market promotion of             Industr
                                                                              Medicine Industry
 Name       Dikang injection (Taikejining injection)               y
                        11. Teratogenicity test
                        12. Carcinogenic test
                        13. Gene mutation test
                        14. Pharmacokinetic research
                        15. Application for domestic patent as well as completion of compose
            experiment of any other derivatives
                        16. Presently, samples and standard products prepared and declared for
            clinic test have been tested in National Institute for the Control of Pharmaceutical and
            Biological Products, and test report has been proved conforming requirement.
                        17. Application of PCT international patent.

                 In the antivirus test, the injection presents favorable antivirus effect to virus
                 as follows:
                 Adenovirus Type 3
                 Adenovirus Type 7
                 Adenovirus Type 11
                 Respiratory syncytial virus
                 Influenza virus A Type 1
                 Influenza virus A Type 3
                 Herpes Simplex Type 1
                 Coxsackie B virus
                 I. Cooperation in R&D
                       1. Production approval in domestic market has been got.
                       2. Further domestic R&D is carried out on expansion of indication and type
            of formulation.
                       3. Registration on clinic declaration and intellectual property right
Cooperati
            protection in overseas markets
   on
                       II. Cooperation in market development
Proposal
                       1. Cooperative sales promotion in domestic/overseas markets
                       2. Market division on sales promotion in domestic/overseas
                     III. Strategic cooperation
                       Strategic cooperation in terms of brand, management, sales network and
            finance.
            Person to                                           028-85123802     028-87846366
 Contact                          Yin Hai             Tel.
             contact                                                     13908005491
Informati
                             028-85123889
   on          Fax                                  E-mail                yinh@dkyaoye.com
                             028-87846942
2.2         Research on anti-gout capsules and GAP raw materials
                                                                            Unit: USD 10,000

  Project        Research on anti-gout capsules and GAP raw
                                                                     Industry      Medicine Industry
  Name                            materials
Construction   Research and construction of GMP capsule production line at Clinic Stage 2 and
 Contents      Clinic Stage 3
                Company         Sichuan Dikang Sci&Tech                 Legal
                                                                                              Sun Jilin
                 Name        Pharmaceutical Industry. Co., Ltd.     Representative
                 Total                      Total                    Asset-liability
                 Assets                   Liabilities                    ratio
                            Taikejining injection under research for Class-I new traditional Chinese
                            medicine of national standard
                            “Absorbable inner screws for bone bolting” under high-tech projects of
                            National “863” Program
                            Class-II new medicine of national standard, including Tuoerding,
                Leading
                            piglitazone hydrochloride, sodium rabeprazole, anti-cold granules for
  Current       Products
                            infants, Yintai lotion, Ditong Rhinities Water, compound
Situation of
                            sulfamethoxazole, compound aminophenazone and Povifone Iodine
 Company
                            Suppositories etc.
                            Shenmai, shenqin, danqi, SDE, plentiful clinic Pazufloxacin products,
                            Yijin granule, Caseal capsule, Tongfengliling (anti-gout drug).
               Production    In the third year since the plant is put into production, the annual sales
                Capacity       amount will reach USD eight million, with net profit of USD three
                & Scale                                       million.
                Operating                                Year                          Year
                            Year 2001
                 Income                                  2002                          2003
                                                         Year                          Year
                  Profit    Year 2001
                                                         2002                          2003
               According to the survey, gout disease emerges in continuously increasing incidence
               rate and is free from restriction of age, region and labor type, which together with its
               complex incidence gene make the disease hard to be cured but easy to recrudesce. In
               nowadays medicine markets both domestic and abroad, there are only a few specific
               for treatment of gout, especially pure natural phyto medicines. Thus, the gout patients
               have suffered a lot, no matter in the big cities boasting advanced medical technology
 Market        or in the remote areas lacking in medicines.
Forecast &     In our country, the increasing trend of gout incidence rate is in some extent related to
 Analysis      improvement of people’s living condition. Gout is a kind of paroxysmal disease that
               makes the patient suffer acute pain for a couple of days in one year, however, its
               potential harm cannot be omitted at all. The gout patients not only have symptoms like
               gout arthritis and lithiasis but also suffer severe complication resulted from long-term
               corrosion to in-vivo arthrosis and splanchnic organs by the high uric acid and
               tophaceous gout. As per the statistics, 90% of the gout patients will suffer chronic
               kidney disease such as impotence, nephritis, concretion and heart disease; 50% will
               become disabled because of severe distortion of arthrosis, 30% might die of uraemia
               or renal failure. Therefore, the product will enjoy a quite bright prospect once being
               marketed.
Construction   The pre-clinic research has been completed and the production base is to be
 Conditions    constructed.
                                                                   Foreign Investment          123
   Total
                                     246                             Self-Raised by
Investment                                                                                     123
                                                                      Enterprises
 Economic      In the third year since the plant is put into production, the annual sales amount will
  Benefits     reach USD eight million, with net profit of USD three million.
Preliminary    1. Complete preliminary research on products. 2. Pass the examination and approval of
   Tasks       State Food & Drug Administration.
Cooperation
                                           Joint-venture and cooperation.
 Proposal
               Person to                                         028-85123802     028-87846366
                                     Yin Hai            Tel.
  Contact       contact                                                   13908005491
Information                     028-85123889
                  Fax                                  E-mail               yinh@dkyaoye.com
                                028-87846942
2.3         Clinic research on Danqi injection
                                                                                    Unit: USD 10,000

  Project
                     Clinic research on Danqi injection           Industry       Medicine Industry
  Name
Construction
                    To be constructed
 Contents
                               Sichuan Dikang Sci&Tech
                Company                                               Legal
                              Pharmaceutical Industry. Co.,                                Sun Jilin
                 Name                                             Representative
                                         Ltd.
                 Total                    Total                   Asset-liability
                 Assets                 Liabilities                   ratio
                            Taikejining injection under research for Class-I new traditional
                            Chinese medicine of national standard
                            “Absorbable inner screws for bone bolting” under high-tech projects
                            of National “863” Program
                            Class-II new medicine of national standard, including Tuoerding,
  Current       Leading
                            piglitazone hydrochloride, sodium rabeprazole, anti-cold granules for
Situation of    Products
                            infants, Yintai lotion, Ditong Rhinities Water, compound
  Project
                            sulfamethoxazole, compound aminophenazone and Povifone Iodine
 Company
                            Suppositories etc.
                            Shenmai, shenqin, danqi, SDE, plentiful clinic Pazufloxacin products,
                            Yijin granule, Caseal capsule, Tongfengliling (anti-gout drug).
               Production   In the third year since the plant is put into production, the annual sales
                Capacity        amount will reach USD 1.05 million, with net profit of USD 4.8
                & Scale                                      million.
                Operating     Year                     Year                         Year
                 Income       2001                     2002                         2003
                              Year                     Year                         Year
                  Profit
                              2001                     2002                         2003
               Danqi injection comprises two kinds of traditional Chinese medicines, przewalsk
               sage root and panax pseudo-ginseng, with major function of blood activating and
               stasis eliminating. It can be used against stagnation & blood stasis,heart & chest
               impediment pain, dizziness and headache (optimum medicine for accessorial
               treatment of coronary heart disease and high blood pressure), bellyache during
 Market
               menstruations, wound and trauma as well as any other diseases. Like products in
Forecast &
               the market are mostly produced in form of tablet presently, therefore, the Company
 Analysis
               will offer the patients better service with new type of formulation and higher
               quality.
               Along with people’s stress on the natural phyto medicines in addition to its daily
               increasing clinic application, the product enjoys extensive market demand and a
               great prospect presently.
Construction   The pre-clinic research has been completed and the production base is to be
 Conditions    constructed.
                                                                 Foreign Investment          120
   Total
                                   220                              Self-Raised by
Investment                                                                                   100
                                                                     Enterprises
Economic      In the third year since the plant is put into production, the annual sales amount will
 Benefits     reach USD 1.05 million, with net profit of USD 4.8 million.
Preliminary   1. Complete preliminary research on products. 2. Pass the examination and
   Tasks      approval of State Food & Drug Administration.
Cooperation
                                         Joint-venture and cooperation.
 Proposal
                                                                          028-85123802
              Person to
                                    Yin Hai           Tel.                028-87846366
  Contact      contact
                                                                          13908005491
Information
                               028-85123889
                 Fax                                 E-mail            yinh@dkyaoye.com
                               028-87846942
2.4         Gene Detection kit (PCR-RFLP) for Neural Tube Defects
                                                                                   Unit: USD 10,000

  Project       Gene Detection kit (PCR-RFLP) for Neural
                                                                 Industry      Medicine Industry
  Name                        Tube Defects
Construction
                   Production and marketing can be proceeded once the project is fully funded.
 Contents
                Company        Sichuan Yukang Biological             Legal
                 Name             Technology Co., Ltd.           Representative
                 Total                   Total                   Asset-liability
                 Assets                Liabilities                   ratio
                            1. Diagnosis kit for methyl transferase          [Biological Products of
                            National Standard (in-vitro diagnostic test kit) Class-I new medicine]
                Leading
 Current                    2. Gene Detection kit (PCR-RFLP) for Neural Tube Defects
                Products
Situation                   [Biological Products of National Standard (in-vitro diagnostic test kit)
    of                      Class-I new medicine]
Company        Production
                             Production and marketing can be proceeded once the project is fully
                Capacity
                                                         funded.
                & Scale
               Operating      Year                    Year                         Year
                Income        2001                    2002                         2003
                              Year                    Year                         Year
                 Profit
                              2001                    2002                         2003
               Neural Tube Defects (NTDs) is a kind of birth defect with most severe harm, which
               might results in death, mental retardation or lifelong paralysis of the newborn.
               China is the country holding the highest incidence rate all over the world, with one
               case for every 3~5 minutes presently. There are 22 ~25 million infants born in
               China each year, the parents of whom are all the detection target for the product.
               Moreover, the Birth Defect Intervention Project and Action Plan of the State
 Market        Population and Family Planning Commission and the Ministry of Public Health
Forecast &     always regard prevention of NTDs as their primary task.
 Analysis      NTDs cannot be rectified once it occurs, thus, prevention, especially pre-pregnancy
               prevention is extremely significant. Detection of high risk group in parental
               generation which might bearing filial generation with NTDs is the key factor for
               success of prevention. Utilizing PCR-RFLP technology, the test kit can be used to
               detect the gene mutation situation of MTHFR (5, 10 methylenetetrahydrofolate
               reductase) and MTRR (Methionine synthase reductase) to both parties of the
               couple, thereby judge that whether the couple is among the high-risk group.
Construction
               Production and marketing can be proceeded once the project is fully funded.
 Conditions
                                                                 Foreign Investment          370
   Total
                                     370                            Self-Raised by
Investment                                                                                    0
                                                                     Enterprises
              In 2006 after the plant is put into production, the annual sales amount will exceed
Economic      USD six million, with net profit of USD 1.8 million. In 2007 after the plant is put
 Benefits     into production, the annual sales amount will exceed USD ten million, with net
              profit of USD 3.7 million. Investment is expected to be returned in three years.
Preliminary
              Production has been completed, and products can be marketed.
   Tasks
Cooperation
                                           Investment and financing
 Proposal
                                                                        028—86203598
              Person to
  Contact                        Qin Mei             Tel.                   13308056095
               contact
Information                                                           PAS 028--81259592
                 Fax          028--86203238        E-mail               ucan@ucan..cn
2.5         Diagnosis kit for methyl transferase
                                                                             Unit: USD 10,000

  Project
                    Diagnosis kit for methyl transferase         Industry      Medicine Industry
  Name
Construction
                    Production and marketing can be proceeded once the project is fully funded.
 Contents
                Company        Sichuan Yukang Biological             Legal
                 Name             Technology Co., Ltd.           Representative
                 Total                   Total                   Asset-liability
                 Assets                Liabilities                   ratio
                            1. Diagnosis kit for methyl transferase          [Biological Products of
                            National Standard (in-vitro diagnostic test kit) Class-I new medicine]
                            2. Gene Detection kit (PCR-RFLP) for Neural Tube Defects
                Leading
                            [Biological Products of National Standard (in-vitro diagnostic test kit)
  Current       Products
                            Class-I new medicine]
Situation of
 Company

               Production
                             Production and marketing can be proceeded once the project is fully
                Capacity
                                                         funded.
                & Scale
                Operating     Year                    Year                         Year
                 Income       2001                    2002                         2002
                              Year                    Year                         Year
                  Profit
                              2001                    2002                         2002
               According to incomplete statistics, there are seven million people died of cancer
               each year around the world. While in China, at least 1.6 million new cases of cancer
               are diagnosed per year. Chemotherapy is one of the most important means for
               treatment of cancer. Making clear the drug tolerance of cancer cell is not only the
               exigent demand for clinic cancer treatment and the necessary approach towards
               clinic curative effect improvement as well. As the only one product approved to be
               used for clinic diagnosis of MGMT presently, diagnosis kit for methyl transferase
 Market        will be put into routine application once being marketed.
Forecast &     Various researches and bibliographies show that the drug tolerance of cancer cell
 Analysis      towards alkylating agent is closely related to the content of MGMT protein in
               cancer cell. High content brings about high drug tolerance, while low content
               results in sensitivity. Diagnosis kit for methyl transferase detects the MGMT
               content in cancer tissues by immunohistochemistry method, setting the direction for
               preparing forecasting and personalized clinic chemotherapy plan. The test kit, both
               sensitivity and specificity of which reach 100%, characterized in its convenient
               using. It can be applied by Pathology Departments of the hospitals, enjoying a
               bright prospect.
Construction
               Production and marketing can be proceeded once the project is fully funded.
 Conditions
                                                                Foreign Investment         370
   Total
                                   370                            Self-Raised by
Investment                                                                                  0
                                                                   Enterprises
              In 2006 after the plant is put into production, the annual sales amount will exceed
Economic      USD eleven million, with net profit of USD three million. In 2007 after the plant is
 Benefits     put into production, the annual sales amount will exceed USD thirteen million, with
              net profit of USD 3.7 million. Investment is expected to be returned in three years.
Preliminary
              Production has been completed, and products can be marketed.
   Tasks
Cooperation
                                           Investment and financing
 Proposal
                                                                        028—86203598
              Person to
  Contact                        Qin Mei             Tel.                   13308056095
               contact
Information                                                           PAS 028--81259592
                 Fax          028--86203238         E-mail              ucan@ucan..cn
2.6      Industrialized production base for floristic-intermediate in modernization of
traditional Chinese medicine
                                                                                   Unit: USD 10,000

               Industrialized     production  base     for
  Project
               floristic-intermediate in modernization of        Industry      Medicine Industry
  Name
               traditional Chinese medicine
Construction        Carry out industrialized production of floristic-intermediate by using
 Contents      investment.
               Company       Chengdu Hongsen Agricultural           Legal
                Name             Technology Co., Ltd.           Representative
                 Total                   Total                   Asset-liability
                 Assets                Liabilities                   ratio
                            Soybean Isoflavone (byproduct: soybean Saponin), Tanshinone
                            (byproduct: Danshensu (Propanoic acid)),
                Leading
                            Intermediate products of plants including tea extracts, capsaicin
                Products
                            (byproduct: paprika red), arteannuin etc.
  Current
Situation of
                            3-5 intermediate products from natural products will be manufactured
 Company
               Production   each year. Once the production base is completed and enters into
                Capacity    production stage, the sales income of various floristic-intermediate
                & Scale     products will reach USD 6.9 million, achieving tax profits of USD
                            three million by investing total cost of USD 3.8 million.
               Operating      Year                    Year                         Year
                Income        2001                    2002                         2003
                              Year                    Year                         Year
                 Profit
                              2001                    2002                         2003
               As the carrier of advanced technology for phyto medicines, herb extracts are raw
               materials for preparation of phyto medicines. Compared with phyto medicines,
               chemical medicines are of great toxic and sideeffect and are apt to generate drug
               tolerance. Contrarily, natural medicines made from herb extracts are superior in
               their high technology, high product added value, extensive application in
               international markets and expansive market prospect. Over the past few years, herb
               extracts and related products have been through rapid development in the market.
 Market        The natural phyto medicines with huge potentiality have become the ideal choice of
Forecast &     modern medical care in the developed countries. It is estimated that the trading
 Analysis      volume of natural phyto medicines in the global phyto medicine market will exceed
               USD 26 billion. Currently, our phyto medicines accounts for less than 10% of the
               international market, and that in the Asian markets is about USD 0.7~0.8 billion. In
               2004, the gross export value of herbal extracts in our country reaches USD 230
               million, accounting for less than 2% of the international market. Following the
               natural trend towards modernization of phyto medicines in development of
               traditional Chinese medicine, the Company is now taking this opportunity in an
               attempt to accomplish great achievements in the industry so as to boost the
               industrial development of herbal extracts in Chinese herbal medicine industry.
Construction
                                                      Good
 Conditions
                                                                 Foreign Investment         230
   Total
                                    300                            Self-Raised by
Investment                                                                                  70
                                                                    Enterprises
               Once the production base is completed and enters into production stage, the sales
 Economic      income of various floristic-intermediate products will reach USD 6.9 million,
  Benefits     achieving tax profits of USD three million by investing total cost of USD 3.8
               million.
               Industrialized production base for floristic-intermediate is located at Baili Road,
               Development Zone, Chengdu National Cross-Strait Scientific Industry
               Development Park, with production base covering an area of 51.68 mu. Presently,
Preliminary
               USD 700,000 has been invested for: land purchase (51.68mu), basic environment
   Tasks
               realignment in plant area, standard workshop and accessorial production plant
               equipped with necessary fire-fighting facilities in, R&D center, office building and
               manufacturing equipment for fabrication.
Cooperation
                                          Joint venture and cooperation.
 Proposal
               Person to
  Contact                      Huan Guoqiang          Tel.                 13880300233
                contact
Information
                  Fax                                E-mail
2.7        Qiangli ketong (pain alleviation) capsule
                                                                                    Unit: USD 10,000

Project
               Qiangli ketong (pain alleviation) capsule          Industry      Medicine Industry
Name
Construction   Construction of a production line with annual production capacity of three hundred
Contents       million Qiangli ketong (pain alleviation) capsules.
               Company       Chengdu Jiameng Industrial           Legal
               Name          Technology Co., Ltd.                 Representative
               Total                    Total                     Asset-liability
               Assets                   Liabilities               ratio
               Leading       Qiangli ketong (pain alleviation) capsule
Current        Products
Situation of   Production
Company        Capacity
               & Scale
               Operating      Year                    Year                          Year
               Income         2001                    2002                          2003
                             Year                     Year                          Year
               Profit
                             2001                     2002                          2003
               As one of the common symptoms among those numerous diseases, pain is a kind of
               complex feeling. All the life long, every one has experience of pain more or less,
               heavy or light. As per statistics, 30% of the adults suffer chronic pains. In China,
               there are at least one hundred million people are afflicted by pains. In case of failure
               of timely and efficient treatment, many chronic and stubborn pains might be
               evolved from long-term local common pain into local complex pain syndrome or
               central pains, and eventually become tough pain diseases. Therefore, medicines
               designed for treatment of pains enjoy a bright prospect. As introduced by the
               experts in pharmacology, traditional pain alleviation drugs are classified into three
Market         kinds below: Non-steroid analgesic drug that is represented with Aspirin and Fenbid
Forecast &     which is likely to result in gastrorrhagia; Central analgesic drug with little
Analysis       stimulation to gstrointestinal tract and strong analgesic effect but without any
               addiction, which can be taken by the patients with no tolerance towards the first
               kind of drug; Opioid analgesics such as pethidine and morphia, which is of strong
               analgesic effect and also strong addiction. Non-steroid analgesic drug is the most
               frequently used pain alleviation drug in daily life in spite of its numerous adverse
               reaction. Compared with above drugs, Qiangli ketong (pain alleviation) capsule is
               produced towards indication that nearly covers the entire application scope of
               analgesics like Aspirin and morphia. Moreover, it is the leading innoxious
               analgesics without dependence and addiction. Holding such obvious competitive
               advantage, the product will enjoy a bright prospect once being marketed.
Construction   The project site is located at Sanzhong Park New Industrial Zone of Jintang County,
Conditions     a provincial development zone, which is of complete infrastructures.
Total          1500                                               Foreign Investment        1500
Investment                                                       Self-Raised by
                                                                 Enterprises
              It is expected that the sales income after the plant is put into production will reach
Economic
              30 million, with tax profit of six million. The investment will be returned in four
Benefits
              years. Construction will last for one year.
              On completion of preliminary tasks for the products, the declaration procedure for
              “code No. for medicine approval” will be initiated, namely, to declare to the
Preliminary   Ministry of Public Health and State Food & Drug Administration for examination
Tasks         and evaluation in accordance with the requirements for entering into WTO.
              Currently, several related tests have been carried out, while the final clinic tests are
              undergoing.
Cooperation
              Cooperation and joint-venture will be taken as the major means.
Proposal
              Person to
Contact                     Zhang Xiaoping          Tel.          (8628) 89282215
              contact
Information
              Fax            (8628) 84931320        E-mail       banst@sina.com
2.8    Processing of medicinal materials as chuanxiong (Sichuan lovage
rhizome) and “Sanmu”
                                                                           Unit: USD 10,000
                   Processing of medicinal materials as
  Project                                                                            Planting base for
                 chuanxiong (Sichuan lovage rhizome) and           Industry
  Name                                                                                TCM materials
                                “Sanmu”
               Purchase and processing of medicinal materials such as chuanxiong (Sichuan
               lovage rhizome) and “Sanmu” will be developed relying on the existing base, based
Construction
               on which research, development and production of prepared Chinese medicine with
 Contents
               chuanxiong (Sichuan lovage rhizome) and “Sanmu” as its major raw materials will
               be further developed.
               Company                                                 Legal
                               Chengdu Huatai Corporation
                Name                                               Representative
                 Total                    Total                    Asset-liability
                 Assets                 Liabilities                    ratio
                Leading
  Current       Products
Situation of   Production
 Company        Capacity
                & Scale
               Operating      Year                      Year                         Year
                Income        2001                      2002                         2003
                              Year                      Year                         Year
                 Profit
                              2001                      2002                         2003
               Chuanxiong (Sichuan lovage rhizome) belongs to the Umbelliferae plants with
               effect of activiating qi-flowing and resolving stagnation, dispelling pathogenic wind
               and removing dampness, promoting blood circulation and relieving pain, which can
               mainly be used for treatment of headache, dizziness, hypochondriac pain and
               bellyache, amenia, dystocia and carbuncles and sores. Its rhizome can be baked
               (basked) dry and made into medicine, whose contents like naphtha and ferulic acid
               have effect of promoting blood circulation and activiating qi-flowing, dispelling
               pathogenic wind and relieving pain. It is an important medicinal material for TCM
 Market        dispensing as well as the traditional staple TCM materials frequently used in our
Forecast &     country.
 Analysis      “Sanmu” medicinal materials include Huangbai (Phellodendron Bark), eucommia
               bark and magnolia bark.Huangbai (Phellodendron Bark) is one of the TCM
               materials in common use, with effect of clearing heat-fire and relieving cold and
               heat. Eucommia bark is a sort of perennial woody plant in Eucommia ulmoides
               Oliv, whose bark will be processed as medicine. It is of major medicine property
               including nourishing liver and kidney, strengthening tendons and bones, descending
               blood pressure and preventing miscarriage. Magnolia bark of deciduous arbor is
               suitable to be planted in mountainous areas with moist air and cold weather,
               especially favorable in the rich soil with plentiful humus. It has effect of activiating
               qi-flowing, eliminating dampness, relieving mass and alleviating dyspnea.
               Presently, there are great demand for health products and prepared Chinese
               medicine made from raw materials including Chuanxiong (Sichuan lovage rhizome)
               and “Sanmu”. Contradiction between supply and demand becomes outstanding.
               Along with the stress to phyto medicines as well as the continuously increasing
               application both domestic and abroad, such medicinal materials will enjoy a
               brighter prospect.
Construction
 Conditions
                                                                  Foreign Investment        1200
   Total
                                   1800                             Self-Raised by
Investment                                                                                   600
                                                                     Enterprises
               It is estimated that the annual sales income up on completion of the plant will reach
 Economic
               USD 12.5 million, with annual profit above USD 1.25 million. Investment will be
  Benefits
               returned in about three years.
Preliminary
   Tasks
Cooperation
 Proposal
               Person to
  Contact                                              Tel.
                contact
Information
                  Fax                                E-mail
2.9     High-tech industrialization demonstrative                    project        for    standard
extractive of chuanxiong (Sichuan lovage rhizome)
                                                                             Unit: USD 10,000
                 High-tech industrialization demonstrative
  Project                                                                          Planting base for
               project for standard extractive of chuanxiong      Industry
  Name                                                                              TCM materials
                         (Sichuan lovage rhizome)
               The plant to be constructed in Pengzhou will be mainly regulated by Provincial
               Development and Reform Commission and undertaken by Sichuan Tianle
               Pharmaceutical Group Co., Ltd.. By means of “Corporation + Base + Farmer”,
               chuanxiong (Sichuan lovage rhizome) germchit breed base with an area of 800mu
               and standard planting base with an area of 10000mu will be constructed in
               accordance with GAP standard. Fine processing plant for standard Rhizoma
               chuanxiong P.E and bacterial manure manufacturing plant particularly for
               chuanxiong (Sichuan lovage rhizome) will be constructed. Thereon, an annual
Construction   production capacity of 700tons chuanxiong (Sichuan lovage rhizome), 4000 tons
 Contents      chuanxiong (Sichuan lovage rhizome) medicinal materials, 359 tons standard
               Rhizoma chuanxiong P.E and 4000 tons bacterial manure for chuanxiong (Sichuan
               lovage rhizome) will be realized. Rhizoma chuanxiong P.E series (chuanxiong oil:
               106 tons/year, enterprise level; gross chuanxiong alkaloid: 54 tons/year, enterprise
               level; gross Rhizoma chuanxiong P.E: 200 tons/year, enterprise level).AM bacterial
               manure: 4000 tons/year. Chuanxiong Polyporus umbellatus: 770 tons/year in
               conformity with GAP standard. To achieve the aforesaid goals, the Company plans
               to invite investment from outside and pursue mutual development with the investors
               based on reciprocity and mutual benefit.
               Company       Sichuan Tianle Pharmaceutical           Legal
                Name                Group Co., Ltd.              Representative
                 Total                   Total                   Asset-liability
                 Assets                Liabilities                   ratio
                Leading
  Current       Products
Situation of   Production
 Company        Capacity
                & Scale
               Operating      Year                    Year                         Year
                Income        2001                    2002                         2003
                              Year                    Year                         Year
                 Profit
                              2001                    2002                         2003
               Chuanxiong (Sichuan lovage rhizome) belongs to the Umbelliferae plants with
               effect of activiating qi-flowing and resolving stagnation, dispelling pathogenic wind
 Market
               and removing dampness, promoting blood circulation and relieving pain, which can
Forecast &
               mainly be used for treatment of headache, dizziness, hypochondriac pain and
 Analysis
               bellyache, amenia, dystocia and carbuncles and sores. Its rhizome can be baked
               (basked) dry and made into medicine, whose contents like naphtha and ferulic acid
               have effect of promoting blood circulation and activiating qi-flowing, resolving
               stagnation. It is an important medicinal material for TCM dispensing. Chuanxiong
               (Sichuan lovage rhizome) mainly grows in Dujiangyan, Pengzhou, Xindu of
               Sichuan Province, in which the output accounts for about more than 80% of the
               national gross output. Having been used for a long history, Chuanxiong (Sichuan
               lovage rhizome) is of mature technology in planting and cultivation. As a kind of
               our traditional staple TCM materials as well as our major variety in TCM materials
               export, chuanxiong enjoys high reputation both domestic and abroad. Its annual
               consumption is about 9000 tons in the country.
Construction
 Conditions
                                                                  Foreign Investment          370
   Total
                                    1250                             Self-Raised by
Investment                                                                                    880
                                                                      Enterprises
               1. Economic Benefits: It is estimated that after the plant is put into production, the
               sales income will reach USD 16 million, with annual profit of USD 4.8 million,
               income tax of USD 1.7 million and profit after tax of USD 3.1 million.
               2. Social benefits: develop planting of preponderant medicinal materials, adjust
 Economic
               industry structure of agriculture, improve farmers’ income, provide more
  Benefits
               occupation to the agricultural labor force, improve financial income, solve
               employment of town population and promote the ecological reconstruction and
               sustainable utilization of natural resources in the upper and middle reaches of The
               Yangtze River.
               Polyporus Umbellatus Base in Wenchuan, Rhizoma chuanxiong P.E Base in
               Pengzhou and Aoping Bcterial Mnure Plant in Pengzhou have all signed land-use
               agreements with the local governments. Some of them have fulfilled payment,
               cooperated with the design institute in land survey and provided data about
Preliminary
               hydrology, environment and weather. At present, the Company has allocated
   Tasks
               necessary funds for land requisition related to the project and buildings in the land
               is to be removed. Meanwhile, design of construction drawing has been initiated
               formally on completion of related documents preparation; moreover, inspection,
               research and type selection of equipment has almost been completed.
Cooperation
                                           Joint-venture or cooperation.
 Proposal
               Person to
  Contact                         Liu Yong             Tel.                  83100591
                contact
Information
                  Fax                                 E-mail
2.10        Base construction for traditional Chinese medicine industry
                                                                                Unit: USD 10,000
  Project         Base construction for traditional Chinese                            Planting base for
                                                                     Industry
  Name                       medicine industry                                          TCM materials
               After being through feasibility study research, the plant is determined to be
               constructed in Hejiang County and will mainly regulated by Gulin County Planning
               Bureau of Luzhou and undertaken by Sichuan Longlife Pharmaceutical Co., Ltd of
               Gulin. As per the development plan, the plant is mainly composed of two parts. 1.
               TCM materials: To develop 47,700mu of planting base for high-quality and
               pollution-free TCM materials across the county up to 2010,of which, 5000mu for
               Gancaohuang, 5000mu for Radix Asparagi, 10000mu for “Sanmu” medicinal
Construction
               materials, 2000mu for Chinese goldthread and 4000mu for tuber of elevated
 Contents
               gastrodia.2. Sichuan Longlife Pharmaceutical Co., Ltd expands its GMP production
               lines for Gansu granules and Gansu suspended release granules; with annual
               production capacity of 170,000 pieces (189 million bags) for Gansu capsules (Gulin
               gansu) and 53,000 pieces (31,800,000 capsules) for Gansu suspended release
               granules. Construction of the plant will be gradually completed between
               2005-2010, and the company plans to achieve mutual development through inviting
               merchants and investment.
                                      Sichuan Longlife
                 Company                                                 Legal
                                  Pharmaceutical Co., Ltd of
                  Name                                               Representative
                                           Gulin
                                            Total                    Asset-liability
                Total Assets
                                          Liabilities                    ratio
                 Leading
  Current                      Gulin gansu
                 Products
Situation of
                Production
 Company
                Capacity &
                  Scale
                 Operating      Year                     Year                          Year
                  Income        2001                     2002                          2003
                                Year                     Year                          Year
                   Profit
                                2001                     2002                          2003
               Gansu granules is elaborated with the major raw materials Gulin gancaohuang
               (Penthorum Chinese Pursh), a kind of precious medicinal material growing in the
               primary forests of Wumeng Mountain, using advanced extracting and preparing
 Market        equipment. It has been widely acknowledged as the TCM preparation with certain
Forecast &     curative effect to hepatitis B.As the first kind of prepared Chinese medicine
 Analysis      protected by its origin in China, the granules are of effects such as descending
               enzyme, protecting liver, releasing icterus, strengthening spleen. Thus, they can be
               used against acute virus hepatitis, chronic active hepatitis and hepatitis B.
               In recent years, liver diseases including virus hepatitis, liver fibrosis, fatty liver and
               pathological changes of alcoholic liver disease, drug-induced liver disease and liver
               cancer have gradually become one of the major diseases threatening people’s
               health. China is a country with most liver disease cases, including 1.2 million cases
               of acute virus hepatitis diagnosed each year. There are about 20 million cases of
               chronic hepatitis currently, and about 500,000 cases of liver disease will die each
               year. There are about 600,000 newborns carrying HbsAg each year in China, 1/4 of
               which will eventually become chronic. Medical expense directly spent on virus
               hepatitis reaches RMB 50 billion Yuan each year. Anti-virus medicines enjoy a
               quite bright prospect in China.
               Sichuan Longlife Pharmaceutical Co., Ltd is located in Gulin County of Sichuan
               Province, engaging in production of medicines of over thirty varieties and seven
               types of formulation like granule and tablet. Ganhuangcao, the raw material of
               Gulin gansu, is the classical and genuine medicinal material of Gulin County in
               Sichuan Province scattering in Wumeng Mountain areas at an altitude of 1000m,
               whose growing and survival are depended on proper soil, sunlight, temperature and
               rainfall etc.
Construction
               Gulin gansu is of anti-virus effect similar to heptodin that the like prepared Chinese
 Conditions
               medicines cannot surpass. The product has been included in the State Essential
               Drug List, awarded the Certificate of National Protected Traditional Chinese
               Medicinal Products and listed as the only key science & technology achievement
               promotion for liver disease treatment in the whole province by Sichuan TCM
               Administration in 2001.Annual sales income has exceeded RMB 50 million Yuan
               up to now. The State Development & Planning Commission has listed it as the
               “High-tech industrialization demonstrative project for modern TCM”.
                                                                   Foreign Investment         580
   Total
                                     830                             Self-Raised by
Investment                                                                                    250
                                                                      Enterprises
               After the plant is constructed, production value of USD 5.8 million can be
 Economic      achieved, with revenue of USD500,000 and income of USD three million for the
  Benefits     farmers, moreover, production value of medicine industry amounting to USD 45
               million can be achieved, with revenue of USD eleven million.
Preliminary
               Feasibility study research has been completed.
   Tasks
Cooperation
                                           Joint-venture or cooperation.
 Proposal
               Person to
  Contact                      Zhang Ruqiang            Tel.               0830-7222975
                contact
Information
                  Fax                                 E-mail
2.11        Research on manual Songbei (Fritillaria) breed
                                                                                Unit: USD 10,000
  Project         Research on manual Songbei (Fritillaria)                             Planting base for
                                                                     Industry
  Name                           breed                                                  TCM materials
               The plant to be constructed in Pengzhou will be mainly regulated by Provincial
               Development and Reform Commission and undertaken by Sichuan Tianle
               Pharmaceutical Group Co., Ltd.. By means of “Corporation + Base + Farmer”,
               chuanxiong (Sichuan lovage rhizome) germchit breed base with an area of 800mu
               and standard planting base with an area of 10000mu will be constructed in
               accordance with GAP standard. Fine processing plant for standard Rhizoma
               chuanxiong P.E and bacterial manure manufacturing plant particularly for
               chuanxiong (Sichuan lovage rhizome) will be constructed. Thereon, an annual
Construction   production capacity of 700tons chuanxiong (Sichuan lovage rhizome), 4000 tons
 Contents      chuanxiong (Sichuan lovage rhizome) medicinal materials, 359 tons standard
               Rhizoma chuanxiong P.E and 4000 tons bacterial manure for chuanxiong (Sichuan
               lovage rhizome) will be realized. Rhizoma chuanxiong P.E series (chuanxiong oil:
               106 tons/year, enterprise level; gross chuanxiong alkaloid: 54 tons/year, enterprise
               level; gross Rhizoma chuanxiong P.E: 200 tons/year, enterprise level).AM bacterial
               manure: 4000 tons/year. Chuanxiong Polyporus umbellatus: 770 tons/year in
               conformity with GAP standard. To achieve the aforesaid goals, the Company plans
               to invite investment from outside and pursue mutual development with the investors
               based on reciprocity and mutual benefit.
                Company        Sichuan A’ba Tianbei Biology              Legal
                 Name                    Co., Ltd.                   Representative
                 Total                     Total                     Asset-liability
                 Assets                  Liabilities                     ratio
                Leading
  Current
                Products
Situation of
               Production
 Company
                Capacity
                & Scale
                Operating
                               2001                      2002                          2003
                 Income
                  Profit       2001                      2002                          2003
               There are over ten sorts of fritillary in China, among which the tendrilleaf fritillary
               bulb is the most precious, while the Songbei (Fritillaria) of which is the most
               superior. Songbei (Fritillaria), the essence of tendrilleaf fritillary bulb, is the bulb of
 Market        the liliaceae Fritillaria unibracteata Hsiao et K. C. Hsia. It is of effects including
Forecast &     removing phlegm and arresting cough, clearing heat and moistening lung, treating
 Analysis      lung cancer, breast cancer and lymphoma as well as of certain effect to some
               tumour and cancer. Huge markets for Songbei have been built up both domestic and
               abroad. With implementation of state authentication, the company will develop
               Songbei products in the existing expansive markets without spending great efforts
               to develop and maintain the markets. Both economic and social benefits will be
               extremely considerable.
               As a kind of precious, endangered and infrequent medicinal materials as well as the
               best one among the several sorts of fritillary in China, Songbei has been
               acknowledged as famous brand both domestically and internationally. After strict
               selection, it is determined to construct the base in Songpan, the origin of Songbei,
               which is rich in genuine medicinal materials and features in its superior ecological
               condition, geography and transport condition. Supported by the share cooperator
               CAS, the project is of technology advantages. The project is contained in state key
               scientific and technological projects, National “863” Program, National High-tech
Construction
               Industrialization Demonstrative Project as well as the project to be supported by
 Conditions
               state TCM material production. TCM materials production is one of the strategic
               industries of the country, thus, the country promulgates favorable policies
               particularly to encourage manual planting. The market prospect is bright.
               Presently, the company only engages in operating research and development
               projects of manual songbei planting. It is a national high-tech enterprise with twelve
               technical staff, including nine with senior professional title, two with medium
               professional title, one with primary professional title, as well as subject research
               experts group consisting of seven experts with senior professional title.
                                                                  Foreign Investment          370
   Total
                                    1250                             Self-Raised by
Investment                                                                                    880
                                                                      Enterprises
               After the plant is put into production, the annual production value will reach USD
 Economic      eight million, with tax profit of USD 1.8 million. Profit after tax will reach USD 35
  Benefits     million in the business period of twenty years. Investment is expected to be
               returned in five years.
Preliminary    Part of infrastructures construction and basic research have been completed, and
   Tasks       Songbei has been planted for an area of 200mu.
Cooperation
                                           Joint venture or cooperation.
 Proposal
               Person to
  Contact                                              Tel.
                contact
Information
                  Fax                                 E-mail
2.12        Genuine honeysuckle extractive of Sichuan Province
                                                                             Unit: USD 10,000
  Project        Genuine honeysuckle extractive of Sichuan                         Planting base for
                                                                  Industry
  Name                          Province                                            TCM materials
               Project Proposal for the plant has been prepared and submitted to the State
               Development & Reform Commission. The plant to be constructed in Shahe Town of
               Nanjiang County will be regulated by Nanjiang Economic Trade Commission and
               undertaken by Nanjiang Bashan Plant Chemical Plant. As per the plan, a processing
Construction
               plant with production line of extracting chlorogenic acid from honeysuckle and a
 Contents
               production line with annual production capacity of 100 tons of high-content
               chlorogenic acid (40% above) will be established up to GMP standard. The
               Company plans to invite merchants and investment from outside and pursue mutual
               development with the investors.
                Company          Nanjiang Bashan Plant               Legal
                 Name               Chemical Plant               Representative
                 Total                   Total                   Asset-liability
                 Assets                Liabilities                   ratio
                Leading
  Current       Products
Situation of   Production
 Company        Capacity
                & Scale
                Operating     Year                    Year                         Year
                 Income       2001                    2002                         2003
                              Year                     Year                        Year
                  Profit
                              2001                    20012                        2003
               Honeysuckle is evergreen vine with fragrant bud, strong vital force and expansive
               adaptability. With favorable resistance to drought and barren, it can grow well both
               in acid soil and in alkaline soil. The officinal contents extracted from honeysuckle
               by scientific means have effect of clearing heat-toxin and diminishing
               inflammation. Furthermore, it is without any toxic and side-effect. Therefore, it has
               been considered as product with bright prospect both domestic and abroad.
 Market
               Presently, honeysuckle demand is increasing not only in medicine markets but also
Forecast &
               in terms of fresh flavor, chemical and health care. Coming along with shortage is
 Analysis
               the price rise. In 2000, the national honeysuckle output is about 5000tons with a
               price of RMB 30-40 Yuan/kg, nearly double of that in 1999; the national output in
               2001 is about 5500tons with a price 55% higher than that in 2000. With the daily
               brighter foreign markets, it is estimated that the domestic and abroad demand will
               reach 17,000-18,000 tons in the coming few years. There will be a great gap
               between output and demand.
               Through fully utilizing ecological advantages, stressing product advantages,
Construction   innovating mechanism, executing applicable policies, optimizing environment,
 Conditions    building up brand and concentrating on key works, Nanjiang County has
               established three honeysuckle belts stretching ten thousand mu and two tea-leaf
              districts. There are additional green economic areas of 113,000mu in the county in
              2003, and now the green economic production value has reached RMB 370 million
              Yuan, a rise of 16.5% year-on-year. Honeysuckle has been marketed in Guangzhou
              and Chongqing, meanwhile, “he”-brand honeysuckle from Nanjiang has become
              the special tea in Zhongnanhai.
              Nanjiang, a place rich in resources for local planting and wild planting of
              honeysuckle, was awarded as “National Honeysuckle County” in 1981. It is at the
              beginning of 1960s that Nanjiang took the lead in cultivating honeysuckle. In
              October 1999, Coordinating and Leading Group for Scientific & Technological
              Industry Base (Sichuan) in TCM Modernization approved Nanjiang as one of the
              first thirteen “National Honeysuckle Planting Demonstrative Districts for Scientific
              & Technological Industry Base (Sichuan) in TCM Modernization”.
                                                                Foreign Investment         220
   Total
                                   330                            Self-Raised by
Investment                                                                                 110
                                                                   Enterprises
              After the plant is put into production, the annual sales income will reach USD five
Economic      million, with annual profit of USD 800,000 and tax of USD 550,000. Investment is
 Benefits     expected to be returned in 5.58 years, with investment profit rate of 15.68% and
              profit tax rate of 23.57%.
Preliminary   Feasibility study report has been completed and submitted to Provincial
   Tasks      Development and Reform Commission.
Cooperation
                                         Joint venture or cooperation.
 Proposal
              Person to
  Contact                         Liu Bin            Tel.                0827-8251138
               contact
Information
                 Fax                                E-mail
2.13    Construction of gingko GAP base and upgrade & improvement of
gingko product series
                                                                             Unit: USD 10,000
               Construction of gingko GAP base and
  Project                                                                          Planting base for
               upgrade & improvement of gingko product            Industry
  Name                                                                              TCM materials
               series
               The plant to be constructed in Jingyang District of Deyang City will be undertaken
               by Deyang Hengli Gingko Science & Technology Co., Ltd and Sichuan Research
               Institute of TCM Materials. The company, the key enterprise in Deyang City, has
               constructed gingko base by means of “Company + Farmer” in Dongtai Town that
               covers planting area of over ten thousand mu and established workshops for
               extracting gingko flavone that to be exported to Janpan. Meanwhile, supported by
               Sichuan Research Institute of TCM Materials, the company has developed and
Construction
               marketed gingko health tea and health wine.
 Contents
               To improve product quality and expand production scale, the company plans to
               expand and reconstruct the existing extracting workshop so as to construct gingko
               GAP base and develop gingko health product. Total investment for the plant will be
               USD 4.3 million. Preliminary tasks such as gingko flavone extracting equipment
               has been equipped and prepared for normal production. Gingko planting area has
               reached 10,000mu. Gingko health wine and health tea have been developed and
               marketed.
               Company       Deyang Hengli Gingko Science            Legal
                Name            & Technology Co., Ltd            Representative
                 Total                   Total                   Asset-liability
                 Assets                Liabilities                   ratio
               Leading
  Current      Products
Situation of   Production
 Company        Capacity
                & Scale
               Operating      Year                    Year                         Year
                Income        2001                    2002                         2003
                              Year                    Year                         Year
                 Profit
                              2001                    2002                         2003
               It is obvious to all that the demand for gingko, a kind of plant only grows in China,
               has reached peak over the past few years. Influenced by the international markets,
               the gingko industry of China also goes through rapid development in terms of
 Market        preparation, extracts processing and planting. Its function both as medicine and
Forecast &     health product have been widely valued by people, especially the confirmed effect
 Analysis      of gingko flavone for prevention and treatment of cardiovascular diseases. On the
               whole, the product enjoys a bright prospect. Thanks to the impact of foreign
               markets, the preparation of gingko leaf is also developed rapidly in our country. The
               final sales volume in the whole country is about RMB 1.4 billion Yuan in 2003, a
               quite considerable number to such TCM of only one variety.
               Jingyang District of Deyang City is of medium subtropical moist climate. Gingko
               industrialization project is listed as the National Comprehensive Demonstrative
               Base Project for Modern Agriculture as well as featured and superior project.
               Gingko Extracts Project was awarded the First Prize for Town Enterprise Science &
               Technology Progress Prize of Sichuan Province as well as Third Prize for
               Municipal Science & Technology Progress Prize in 1999.At present, the product
               has been in the leading place internationally, whose major index like gingko flavone
Construction   reaches 26%~30%. Terpene lactone accounts for 7%~11% and content of gingko
 Conditions    phenolic acid is lower than 1PPM, in the leading place domestically. Annul output
               of gingko leaf of five tons will all be exported.
               Gingko wine was awarded the Second Prize for Town Enterprise Science &
               Technology Progress Prize of Sichuan Province in 1997 and registration certificate
               of Municipal Science & Technology achievements. Its honors also include
               declaration for invention patent in 1998, “Silver” Prize of 8th National Patent Expo
               in 1999 and “Gold” Prize in National Patent Expo in 2000.An annual output of
               100tons gingko health wine is sold well both inside and outside the province.
                                                                 Foreign Investment         520
   Total
                                    620                            Self-Raised by
Investment                                                                                  100
                                                                    Enterprises
               After the plant is completed, the total annual output value will reach USD 12.5
 Economic
               million, with profit of USD 3.7 million. Investment is expected to be returned in
  Benefits
               three to four years.
               Gingko flavone extracting equipment has been equipped and prepared for normal
Preliminary
               production. Gingko planting area has reached 10,000mu. Gingko health wine and
   Tasks
               health tea have been developed and marketed.
Cooperation
                                          Joint venture or cooperation.
 Proposal
               Person to
  Contact                                             Tel.
                contact
Information
                  Fax                                E-mail
2.14   Industrialized        development           for     deep-processing     of      Zhongjiang
przewalsk sage root
                                                                           Unit: USD10,000
             Industrialized     development        for
  Project                                                             Planting base for
             deep-processing      of      Zhongjiang    Industry
  Name                                                                  TCM materials
             przewalsk sage root
             Project construction location is Economic and Technical Development
             Zone of Zhongjiang County, Sichuan Province; the organizer is Sichuan
             New World Danshen Base Industrial Co., Ltd. The project construction
             contents include: GAP traditional Chinese medicine material processing
             plant, GMP health care products and refined decoction pieces factory, and
             GSP standard storage development. It is estimated that the annual
Construction
             industrial production capacity of deep-processing of Zhongjiang
 Contents
             przewalsk sage root is: GAP traditional Chinese medicine 1000 tons and
             GMP health care products and refined decoction pieces 800 tons. Currently,
             the followings have been completed smoothly: land requisition, factory
             planning, land investigation, workshop design, equipments order and
             manufacturing etc. It has already come to the infrastructure construction
             phase.
              Company Sichuan New World Danshen              Legal
               Name         Base Industrial Co., Ltd.    Representative
                 Total                 Total                      Asset-liability
                 Assets              Liabilities                      ratio
                Leading
  Current       Products
Situation of   Production
 Company        Capacity
                & Scale
               Operating    Year                         Year                       Year
                Income      2001                         2002                       2003
                            Year                         Year                       Year
                 Profit
                            2001                         2002                       2003
               Przewalsk sage root, in large demand nationwide, is one of the most
               commonly employed medicine in clinic and holds an important position
               in traditional Chinese medicinal materials. Przewalsk sage root not only
               can promote blood circulation to dispel blood stasis, but also has new
   Market      curative effect for diseases like coronary heart disease, hepatitis, angiitis
analysis and   and nervous debility etc. Meanwhile, it has certain amount of export.
 forecasting   There are nearly 100 hundred types of products taking Przewalsk sage root
               as raw material: Compound Przewalsk sage root Drop Pills, Ginseng
               Heart-Replenish Pills, Cinnabar Heart-nourishing Pills, Amber
               Tranquilization Pills, Baifeng Pills, Guanxin Dan, Danshen Shuxin
               Capsules, Xin’nao Kang, Przewalsk sage root Tablets, Przewalsk sage
             root Paste, Medicinal Liquor for Bone Aching, Evergreen Liquor,
             Compound Yinchen Molasses, Guanxin Granules, Przewalsk sage root
             Hair-darkening, Przewalsk sage root Cream etc, and the produced types
             of formulations are over 10 including: honeydewed pills, waterdewed
             pills, condensed pills, capsules, tablets, decoction plaster, tincture,
             molasses formulations, injections and granules. Of which, the Compound
             Przewalsk sage root Drop Pills for coronary heart disease is the brand
             with largest sales amount in cardiovascular prepared Chinese medicine
             market in 2003. The sales income of the Pills of that year was RMB 819
             million Yuan, estimating according to the average retail price in the
             market, the total market retail scale was about RMB 1.09 billion Yuan.
             So, there is promising future in przewalsk sage root development and
             application. Because the wild resource of przewalsk sage root is
             decreasing and cannot meet the clinical demand, so planting breeds of it
             are developing rapidly.
             Deyang City has over 300 breeds of Chinese medicine crops of which
             over 200 are wild breeds. Planting area of home planted medicine
             materials covers above 10,000 Mu. Amongst, Zhongjiang przewalsk sage
             root and white peony root are most famous in and out of China for their
             long history of planting and high quality; great quantity have been
             exported to Japan and countries and regions of Southeast Asia; further
             more, they are main raw materials of set prescriptions of prepared
             Chinese medicines.
             Construction of Zhongjiang Przewalsk sage root Base in Deyang has
             been listed the first group of experimental unit of Sichuan Province for
             implementing Good Agricultural Practice for Chinese Crude Drugs
             (GAP), establishing the foundation for state designated TCM
Construction
             modernization technical industry base construction and for promoting
 Conditions
             industrialized development for TCM. Sichuan New World Danshen Base
             Industrial Co., Ltd. holds to the mission of improving TCM position, the
             goal of ascending into international market with products and hammering
             at industrialized development of TCM. The Company takes the construction
             of Zhongjiang Przewalsk sage root Base as penetration point to set up
             high quality nuisance free planting base of international standard level.
             The Base has been listed “National TCM Modernized Technological
             Industry (Sichuan) Base” co-constructed by State Five Ministries
             (Bureau and Institution) and Sichuan Province, and the Key GAP
             Technologies R& D Program of Sichuan People’s Government. Further
             more, it is also the key project of industrialized agriculture of
             governments of county level, city level and province level.
                                                        Foreign Investment      150
   Total
                               400                         Self-Raised by
Investment                                                                      250
                                                            Enterprises
              After completion of the Project, annual production output value of 10
Economic
              million USD and annual profit tax USD 2.5 million can be realized.
 Benefits
              Investment will be returned in 3-4 years
              Until now, the following works have been completed successfully: land
Preliminary   requisition, plant area planning, land investigation, workshop design,
   Tasks      equipments order and manufacturing etc. and it has already come to the
              infrastructure construction phase.
Cooperation
                                        Joint-venture or cooperation
 Proposal
              Person to
  Contact                     Liu Rui              Tel.                7132908
               contact
Information
                Fax                               E-mail
2.15        Construction of GAP Dahurian angelica root planting base
                                                                     Unit: USD 10,000
  Project     Construction project of GAP Dahurian                     Planting base for
                                                          Industry
  Name               angelica root planting base                        TCM materials
             Location of this project is at Renli Town, Yongxing Town and Nanqiang
             Town of Suining City. The administrative unit is Agricultural Bureau of
             Suining City; the organizer is Sichuan Yinfa Resource Development Co.,
             Ltd, a provincial level key leading enterprise of agriculture industry. The
             project plans to construct high quality Dahurian angelica root planting
Construction base 30000 Mu, set up improved seed breeding center for Dahurian
 Contents    angelica root 100 Mu, build GAP planting technological park 500 Mu
             and a Dahurian angelica root processing factory to carry out production
             in conformity with GAP standard procedures and construct the
             infrastructure of the base. A 5000 Mu high quality Dahurian angelica root
             planting base and a 50 Mu demonstration park have been established in
             Longping, part of the infrastructure construction has been carried out.
                Company       Sichuan Yinfa Resource          Legal
                 Name          Development Co., Ltd       Representative
                 Total                Total                Asset-liability
                 Assets             Liabilities                ratio
                Leading
  Current       Products
Situation of   Production
 Company        Capacity
                & Scale
               Operating    Year                  Year                       Year
                Income      2001                  2002                       2003
                            Year                  Year                       Year
                 Profit
                            2001                  2002                       2003
               Dahurian angelica root can be effective for wide range of diseases and
               the domestic and international market have gradually acknowledged its
               effect and benefit. Our country puts emphasis on development of TCM
               and invests great sums of capital to construct modernized base for
               traditional Chinese medicine industry and TCM processing and storage
               and transportation, providing beneficial opportunity and bright future for
   Market
               development of Dahurian angelica root. Recent years, price for Dahurian
analysis and
               angelica root in Chinese TCM material market is rising. In 2004, price of
 forecasting
               Dahurian angelica root in other places kept in RMB 3-4 Yuan and that of
               Sichuan kept in RMB 6-7 Yuan, 40% higher than other places in average.
               Because the national production amount of Dahurian angelica root is
               small and the farmers would not sell their products easily, price of
               Sichuan Dahurian angelica root may get higher, thus brightening the
               market foreground.
               Forest coverage rate of Suining is 27.94%, the first city of Sichuan Province to
               meet the afforestation requirements. The amount of growing stock reaches
               2.982 million m3. The production area teems with chrysanthemum-core
               dahurian angelica root and is the national well-known “Town of
               Dahurian angelica root”. The annual Dahurian angelica root production
               output is above 3200 tons in first-class quality, accounting 70% of
               national commercial Dahurian angelica root.
               At the beginning of 2000, the state put forward the development strategy of
               “Revive TCM, develop TCM and carry out modernized planting of traditional
               Chinese medicine”. Sichuan, as the “treasure gathering base” for TCM, has been
Construction   taken as the first modernized planting base of traditional Chinese medicine herbs.
 Conditions    As for Sichuan Dahurian angelica root, it has been enlisted the Second
               Group of Sichuan TCM herbs GAP Starting Program with no dispute as
               the local medicinal material of Suining. The eye-catching “GAP
               Dahurian angelica root research and development project” of Yinfa
               Company, through four years of hard striving, has completed the SOP
               constitution in all sections from base selection, environmental monitoring
               over the atmosphere, water quality and earth to breeding, seeding,
               fertilizing and harvesting. The whole process of production realizes
               “safe, effective, stable and controllable”, and has obtained the GAP
               certification successfully. The Company is now planning to make out the
               standard practices for planting Dahurian angelica root.
                                                                Foreign Investment        150
   Total
                                   180                            Self-Raised by
Investment                                                                                30
                                                                   Enterprises
               The annual sales amount will reach USD 4.7 million in 2005 to 2007,
               with taxes of USD 1 million for the country annually, net profit USD 0.8
 Economic      million for the enterprise. In the project area, production amount of
  Benefits     Dahurian angelica root will increase 750,000 Kg per year, bringing
               increased income USD 0.43 million. It will employ 5,200 farmers and
               bring USD 75 for each of them.
               A 5,000 Mu high quality Dahurian angelica root planting base and a 50 Mu
Preliminary
               demonstration park have been established in Longping, part of the
   Tasks
               infrastructure construction has been carried out
Cooperation
                                          Joint-venture or cooperation
 Proposal
               Person to
  Contact                       Wang Jiayin           Tel.               0825-5808538
                contact
Information
                  Fax                               E-mail
2.16   Production of medical polyurethane materials and related medical
products
                                                                           Unit: USD 10,000
                                                                              Medical instruments
  Project       Production of medical polyurethane
                                                                Industry        manufacturing
  Name         materials and related medical products
                                                                                   industry
             Medical polyurethane materials and birth control necessities project of
             Sichuan BoAo Biological Materials Company is the “Three Major
             Projects Program” under State Family Planning Commission and the
             “No. 1 Project Program” of Sichuan Province Committee and Sichuan
             People’s Government. In July 2002, pilotscale experiment of the project
             passed expert appraisal, marking great advancement in research of new
Construction
             type medical high molecular materials and related products. After over two
 Contents
             years of research, the Company has developed medical polyurethane
             thermoplast elastic body, and on the basis, developed polyurethane
             condom, playing an important role in promoting development of China
             medical biological materials and related medical products and breaking
             the situation of foreign technology monopoly, realizing the transfer of
             scientific research achievements into productivity.
               Company         Sichuan BoAo Biological              Legal
                Name              Materials Company             Representative
                 Total                   Total                  Asset-liability
                 Assets                Liabilities                  ratio


                Leading
  Current       Products
Situation of
 Company       Production
                Capacity
                & Scale
               Operating      Year                   Year                         Year
                Income        2001                   2002                         2003
                              Year                   Year                         Year
                 Profit
                              2001                   2002                         2003
               Medical plastic products refer to plastic products used for diseases diagnosis,
               treatment and monitoring and health care and recovery. Along with the
               development of medical instruments, importance of medical plastic products in
   Market
               medical service is increasing. In 2003, the production value of medical
analysis and
               instruments of China exceeded RMB 80 billion Yuan and medical plastic
 forecasting
               products took 15% of the quota. In 2005, China’s medical instrument market
               will increase 40% and medical plastic products will increase at the same rate, so it
               is easy to see the great market potential. The new medical polyurethane
               thermoplast elastic body is the best biological material due to its
               excellent biological compatibility, adhesiveness, anti-thrombus and
               mechanical property. Currently, domestic development and application in
               medical polyurethane materials are relatively hanging behind and mainly
               relying on import.
Construction
 Conditions
                                                              Foreign Investment       1500
   Total
                                  1500                          Self-Raised by
Investment
                                                                 Enterprises
               The project has developed successfully the whole set of technics in polyurethane
               condom solution dip forming; it is proved that the technics and product
               quality is stable. The project has designed and made out the pilotscale
               experiment production line for polyurethane condom. The production
               line adopts the intermittent plate frame dip processing and PLC control,
               thus has high degree of automatization and control accuracy, stable and
               reliable in operation.
Preliminary    Project has finished pilotscale experiment technics and equipment
   Tasks       development for polyurethane condom, overcome the difficulties in
               technics and equipment design for industrialization of polyurethane
               condom. The Company designed and manufactured the first equipment, which
               has relatively high degree of automatization and control accuracy, for
               polyurethane condom solution dip forming. The Company has produced
               excellent polyurethane condom with stable product properties. The
               technology and product are the first innovation nationwide, and leading
               the world, having strong international competitiveness.
Cooperation
                                         Joint-venture or cooperation
 Proposal
                                                                      (8628)
               Person to    Ma Fengjun
  Contact                                           Tel.      85403339,1388067682,
                contact     Lu Hongxing
Information                                                      (8628) 82632099
                  Fax                              E-mail       Luhoxing@sohu.com
Appendix 2: Investment process flow and services

1.      Service items and duration

Since 2000, Sichuan Province has promoted vigorously the reform of administrative
approval system and optimized the soft environment for investment. The departments
under Sichuan Provincial People’s Government have sorted out 2470 items for
administrative approval. Determined by Sichuan Provincial People’s Government,
760 items have been cancelled in 8 batches, 184 will be adjusted, 130 will not be
taken as approval items and only 1269 items will be reserved (of which 1194 items
were set up by the State).The administrative approval items concerning production
and operation and living guarantee of foreign merchants and investors have been
cleared up.
Now only the reserved administrative approval items in industrial and commercial
registration, tax registration, land use, foreign exchange management and customs
filing are related to foreign merchants and investors.
Upon the implementation of Administrative License Law on July 1, 2004, except for
those administrative license can be authorized then and there and for those otherwise
prescribed in laws and regulations, administrative authorities usually make out
administrative approval in 20 days from the day of application acceptance. In case
more time is needed, 10 days can be prolonged after approval by person in charge of
the administrative approval authority, and reasons shall be made clear to the applicant.

2.      “One-stop” Service

Sichuan Province is exerting to establish a standard service-oriented government.
The Government Affairs Service Centre of Sichuan Provincial People’s Government
was set up in October 2001 to accept all the administrative approval items of
provincial departments facing the society. Now 57 departments including industrial
and commercial department, tax affairs department, land and resource department and
business affairs department have set up acceptance windows in the Government
Affairs Service Centre. Services cover over 600 items for approval, almost all affairs
relating to establishing enterprises by foreign merchants and enterprises from other
provinces.
Foreign investors and nonlocal investors can either directly go to the
corresponding windows at the Center for their approval items or firstly visit the
Information Desk and the touchscreen for consultation. For any inquiry, you can
ask the on-duty window at the Center for help.
3.    Procedures for Enterprise Establishment

3.1 Procedures for establishment of foreign-invested enterprises
       Foreign investment projects including Sino-foreign joint ventures, Sino-foreign
       cooperative enterprises, exclusively foreign-owned enterprises, domestic
       enterprises established via merger and acquisition by foreign enterprise,
       capital-increase of foreign-invested enterprises, etc.


       Pre-licensing by the Development and Reform Commission and the Economic
       and Trade Commission depending upon the nature of the project (The
       encouraged or permitted projects with total investment of 100 million dollars or
       above and limited ones of 50 million dollars or above shall be forwarded to the
       National Development and Reform Commission. Application of foreign
       investment utilization projects for technological renovation of existing industrial
       enterprises shall be submitted to the Economic and Trade Commission for
       approval. Those stipulated additionally by law shall be handled accordingly.)



       Approval for the name of foreign-invested enterprise by industrial and
       commercial department


       Approval for Articles of Association and contracts and issue of approval certificate by
       commercial department (or forwarded to the Ministry of Commerce, or submitted to other
       authorities like health, insurance regulatory and banking regulatory departments for prior
       approval)




       Registration at industrial and commercial department and issue of the business license




       Acquiring code of organization by quality and technical supervision authorities



                                               Tax registration




        Formalities of self-declaration at local customs. Encouraged foreign-invested enterprises
        shall complete formalities for tax reduction and exemption at local customs.




       Foreign exchange registration at local administration of foreign exchange and
       approval for foreign exchange account opening


                                           Opening of account at banks
3.2   Establish procedures for non-local domestically-funded
enterprises (Limited liability enterprises and enterprises limited
by shares)

                            Non-local domestically funded enterprise




                 Domestic-funded enterprise name approved by industrial and
                                  commercial department




                                 Pre-administrative license
                 (for example license from health administrative department)




                 Domestic funded enterprise registration at industrial and
                               commercial department




                  Apply for organization code at Quality and
                       Technical Supervision Bureau




                    Apply for taxation registration




                    Opening of account at bank




3.3     Documents required for establishment application
Investors can visit appropriate windows at the Sichuan Government Affairs
Service Center for information of documents required for enterprise establishment
application (Refer to the appendix for telephone number and website). Documents
submitted to the Development and Reform Commission, commercial department
and industrial & commercial administration authorities are as follows:
3.3.1   Documents to be submitted to the Development and Reform
        Commission
        ①    Foreign-invested projects
        The application report of foreign-invested projects submitted to the
        Development and Reform Commission for approval shall cover:
        A. Project title, term of operation and background of investor;
        B. Construction scale of project, basic construction items and products,
           technology and techniques adopted, target market of products, and
           planned number of workers;
        C. Site of construction, demands for resources like land, freshwater and
           energy, and consumption amount of main raw materials;
        D. Prices of involved public products or services;
        E. Total investment, registered capital, amount of capital contribution,
           contribution modes and financing scheme of parties, required imports
           and amount of money therefore.
        The following documents shall be enclosed coincidently:
        A. Enterprise registration certificate (business license), commercial
           registration certificate and up-to-date financial statements (including
           balance sheet, profit & loss statement and cash flow statement) of both
           the Chinese and foreign parties, and capital strength statement issued
           by the bank;
        B. Letter of intent on investment and board resolutions on capital
           increase and merger & acquisition projects.
        C. Letter of intent on financing issued by the bank;
        D. Environmental impact assessment report issued by environmental
           protection authority of the state or provincial level;
        E. Land plan for the project issued by the state or provincial land &
           resources administrative authority;
        F. Those contributing with state-owned assets or the right to the use of the
           land shall provide confirmation documents issued by the competent
           authority.
        ②    Domestic-funded project
             For domestic-funded projects need to be approved, it is required to
             submit 5 copies of application report to the project approval authority.
             The project application report shall include the following contents:
             A. Information about the project application unit
             B. Background of proposed project
             C. Construction land use and related planning;
             D. Resources, energy consumption and related conditions
             E. Analysis on ecological environment impact, economical and social
                effects.
             For domestic-funded projects need to be approved, the following
             documents shall be attached when submitting the project application
             report:
             A. Preliminary analysis report on environment impact confirmed by
             environmental protection authority;
             B. Preliminary review opinions on land use issued by land and
             resource authority;
             C. Planning opinions by urban planning authority;
             D. Other documents shall be submitted as per the State provisions.
3.3.2   Documents to be submitted to the commercial department
        ①    Sino-foreign joint ventures and Sino-foreign cooperative enterprises
             The following documents are required for applying to the
             commercial department for establishing Sino-foreign joint ventures
             and cooperative enterprise:
             A.   Letter of application for joint enterprise establishment;
             B.   Feasibility study report and written reply from the
                  Development and Reform Commission or the Economic and
                  Trade Commission;
             C.   Contracts and Articles of Association (signed by legal
                  representatives or authorized persons of investors from both
                  sides);
             D.   Assignment of the directors of board signed by legal
                  representatives from both sides;
             E.   Business licenses or valid certification of registration, credit
                  standing and legal representatives of both sides.
             The following documents shall be enclosed coincidently:
             A.   Notice for Enterprise Name Registration Approval issued by
                  industrial & commercial administration department;
             B.   Imported equipment list (including equipment name,
                  specification, quantity and price) shall be provided, if any;
    C.   For state-holding enterprise contributing with fixed assets, an
         assets appraisal report is required;
    D.   For any of the above documents signed by authorized person,
         letter of authorization of the investor’s legal representative
         (original) is required.
②   Wholly foreign-owned enterprises
    The following documents are required for applying to the
    commercial department for establishing wholly foreign-owned
    enterprise:
    A    Application letter for establishing wholly foreign-owned
         enterprise (signed by the investor’s legal representative or
         authorized person);
    B    An Application Form for the Establishment of a Wholly
         Foreign-Owned Enterprise in China (signed by the investor’s
         legal representative or authorized person);
    C    Articles of Association of the wholly foreign-owned enterprise
         (signed by the investor’s legal representative or authorized
         person);
    D    The investor’s legal certification and credit standing
         certification documents (bank certification, certificate of
         deposit or statement of account, or annual accountant check
         report, or housing ownership certificate, or annually checked
         business     license    of     Taiwan  invested   enterprises.
         World-renowned enterprises with direct investment can be free
         of credit standing certification).
    The following documents shall be enclosed coincidently:
    A.   Notice for Enterprise Name Registration Approval issued by
         industrial & commercial administration department;
    B.   Where a board of direction is set up, an assignment of directors
         of board signed by the investor is required;
    C.   Evidence of identity of the legal person of the investor (e.g.
         passport, ID card);
    D.   Imported equipment list (including equipment name,
         specification, quantity and price) shall be provided, if any;
    E.   Where there are two or more foreign investors jointly applying
         for the establishment of a wholly foreign-owned enterprise, a
         contract copy shall be provided for review;
             F.   For any of the above documents signed by authorized person,
                  letter of authorization of the investor’s legal representative
                  (original) is required.
3.3.3   Documents to be submitted to the industrial and commercial administration
        department
        ①    Foreign investment (foreign funded, joint venture, cooperation)
             enterprise registration
             The following documents shall be submitted for approval of
             foreign-invested enterprises:
             A.   An Application Form for the Establishment Registration of
                  Foreign-invested Enterprise;
             B.   Approval documents (written reply and duplicate 1 of approval
                  certificate) issued by the approval authority. The joint stock
                  limited company which is incorporated in form of fund-raising
                  is required to submit the approval documents by the Securities
                  Management Department of the State Council;
             C.   Approval documents of the concerned project proposal or
                  feasibility study report;
             D.   Contract (that of wholly foreign-owned enterprises excluded)
                  and Articles of Association;
             E.   Notice for Foreign-invested Enterprise Name Registration
                  Approval;
             F.   The investor’s legal certification for practice and credit
                  certification;
             G.   Original Letter of Appointment of legal representative, director
                  of board, supervisor as well as the copies of their Identity
                  evidence;
             H.   Filing Form of Property Right Registration of State-owned Assets
                  (for state-owned enterprises only);
             I.   Certification of right to domicile use;
             J.   Minutes of founding meeting, promoters’ agreement, financial
                  audit report of the company under preparation (for limited
                  companies only);
             K.   Investment verification certificates issued by a legally
                  authorized investment verification authority (applicable for
                  joint stock limited companies and financial institutions);
             L.   Prior approval documents or certificates (for industries
           required of prior approval);
    M.     Other related documents or certificates.
②   Registration of joint-stock companies limited
    The followings documents shall be submitted when registering
    joint-stock companies limited:
         A. Authorization for the attorney by shareholders and copy of
            attorney’s Identity Card;
         B. Pre-approval notification of enterprise name;
         C. Official documents of department authorized by the State
            Council or provincial People’s Government (joint-stock
            company established with raised capital shall submit official
            documents of Securities Management Department of the State
            Council);
         D. Power of attorney from enterprise legal shareholders and copy
            of the attorney’s Identity Card (sealed by shareholder)
         E. Shareholders qualification certificate: legal shareholder shall
            submit business license of enterprise legal person, enterprise
            legal person certificate, and copy of juridical association
            registration certificate, and shall mark “identical with the
            original” on the copy and affix official seal. Natural person
            shareholders shall submit copies of the Identity Card;
         F. Two copies of Articles of Associations (sealed by legal
            representative shareholder, signed and fingerprinted by natural
            person shareholders);
         G. Minutes of establishment meeting (sealed by legal
            representative shareholder, signed and fingerprinted by natural
            person shareholders);-{}-
         H. Minutes of shareholders’ meetings (signed and fingerprinted by
            representative of legal person shareholder and natural person
            shareholders)
         I. Minutes of meetings of the Board of Directors (signed and
            fingerprinted by directors);
         J. Minutes of meetings of the Board of Supervisors (signed and
            fingerprinted by supervisors);
         K. Appointment letter for Chairman of the Board (legal person)
            and manager employment document (signed and fingerprinted
            by directors) appointment letter for the supervisors (signed and
           fingerprinted by supervisors);
       L. Audit report of the expenses for establishing the joint-stock
          company limited;
       M. Assets Verification Report issued by legal and qualified
          verification authority;
       N. Enterprise legal person shareholders set up in accordance with
          the Company Law shall fill in the Letter of Commitment for
          Enterprise Overseas Investment Notification;
       O. Copies of House Lease Agreement or House Property
          Certificate;
       P. Other materials shall be submitted in conformity with laws and
          regulations.
③   Registration of limited liability companies
    The followings documents shall be submitted when registering limited
    liability companies:
       A. Application for Establishment of Enterprise signed by legal
          person of the company;
       B. Authorization for the attorney by all shareholders and copy of
          attorney’s Identity Card (sealed by legal representative
          shareholder, signed and fingerprinted by natural person
          shareholders)
       C. Power of attorney given by enterprise legal shareholders for
          attending shareholders’ meeting (sealed by enterprise legal
          shareholders) and copy of attorney’s Identity Card;
       D. Shareholders qualification certificate: legal shareholder submits
          copies of business license of enterprise legal person, enterprise
          legal person certificate, and copy of juridical association
          registration certificate; natural person shareholders shall submit
          copies of the Identity Cards;
       E. Enterprise legal person shareholders set up in accordance with
          the Company Law shall fill in the Enterprise Letter of
          Commitment for Overseas Investment Notification
       F. Pre-approval notification of enterprise name;
       G. Two copies of Articles of Associations (sealed by legal
          representative shareholders on the last page of the Articles,
          signed and fingerprinted by natural person shareholders);
       H. Minutes of shareholders’ meetings (signed and fingerprinted by
                     attendants)
                 I. Minutes of meetings of the Board of Directors (signed and
                    fingerprinted by directors);
                 J. Minutes of meetings of the Board of Supervisors (signed and
                    fingerprinted by supervisors);
                 K. Appointment Letter for Legal Person (signed and fingerprinted
                    by shareholders if appointed by shareholders' meeting; signed
                    and fingerprinted by directors if appointed by Board of
                    Directors)
                 L. Appointment Letter for manager, supervisor and convener of
                    meetings of the Board of Supervisors (chairman) (signed as the
                    above)
                 M. Assets Verification Report (valid within 90 days)
                 N. Copies of House Lease Agreement or House Property
                    Certificate;
O. Other materials shall be submitted in conformity with laws and regulations.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:1
posted:4/12/2011
language:English
pages:44